Otsuka announces NICE recommendation of Lupkynis® (voclosporin) with mycophenolate mofetil for treating active lupus nephritis LONDON, UK, 3 May 2023 – Otsuka Pharmaceuticals (U.K.) Ltd. announces that the National Institute for Health and C.
Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus .